carmustine has been researched along with Protein-Energy Malnutrition in 1 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Protein-Energy Malnutrition: The lack of sufficient energy or protein to meet the body's metabolic demands, as a result of either an inadequate dietary intake of protein, intake of poor quality dietary protein, increased demands due to disease, or increased nutrient losses.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Forrester, T | 1 |
| Golden, M | 1 |
| Brand, S | 1 |
| Swales, J | 1 |
1 other study available for carmustine and Protein-Energy Malnutrition
| Article | Year |
|---|---|
Reduction in vitro of red cell glutathione reproduces defects of cellular sodium transport seen in oedematous malnutrition.
Topics: Adult; Antimetabolites; Buthionine Sulfoximine; Carmustine; Erythrocyte Membrane; Erythrocytes; Glut | 1990 |